SyVento and OncoArendi have signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02.
Details in following press release.
18 October 2023
SyVento BioTech Partners with Jagiellonian University’s FBBB for a Biotechnological Leap ForwardExciting developments are on the horizon! SyVento BioTech is proud to announce a partnership with the Faculty of Biochemistry, Biophysics, and...